Karo Bio AB Reacquires Rights to SARM Compounds from Radius

STOCKHOLM, Sweden--(BUSINESS WIRE)--Regulatory News: In September 2006 Karo Bio (STO:KARO) and Radius announced a licensing agreement in which Radius acquired the exclusive worldwide rights to a new class of selective androgen receptor modulators (SARMs) developed by Karo Bio. Karo Bio has now reacquired the full rights to these compounds and to all related data generated by Radius.

Back to news